Innovative Pharmaceutical Biotech (HKSE:00399) EV-to-EBITDA : 4.30 (As of Jun. 01, 2024)

Innovative Pharmaceutical Biotech EV-to-EBITDA Chart

Innovative Pharmaceutical Biotech Annual Data
	Trend	Mar14	Mar15	Mar16	Mar17	Mar18	Mar19	Mar20	Mar21	Mar22	Mar23
EV-to-EBITDA		Get a 7-Day Free Trial					-16.63	-28.29	-122.31	9.19	-129.09

Innovative Pharmaceutical Biotech Semi-Annual Data
	Dec13	Sep14	Mar15	Sep15	Mar16	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
EV-to-EBITDA	Get a 7-Day Free Trial															-	9.19	-	-129.09	-

Competitive Comparison of Innovative Pharmaceutical Biotech's EV-to-EBITDA

For the Household & Personal Products subindustry, Innovative Pharmaceutical Biotech's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Innovative Pharmaceutical Biotech's EV-to-EBITDA Distribution in the Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, Innovative Pharmaceutical Biotech's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Innovative Pharmaceutical Biotech's EV-to-EBITDA falls into.

Innovative Pharmaceutical Biotech EV-to-EBITDA Calculation

Innovative Pharmaceutical Biotech's EV-to-EBITDA for today is calculated as:

Innovative Pharmaceutical Biotech's current Enterprise Value is HK$1,337.86 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Innovative Pharmaceutical Biotech's EBITDA for the trailing twelve months (TTM) ended in Sep. 2023 was HK$311.02 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Innovative Pharmaceutical Biotech  (HKSE:00399) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Innovative Pharmaceutical Biotech's PE Ratio for today is calculated as:

Innovative Pharmaceutical Biotech's share price for today is HK$0.199.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Innovative Pharmaceutical Biotech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 was HK$-0.113.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?

Innovative Pharmaceutical Biotech EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Innovative Pharmaceutical Biotech's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Innovative Pharmaceutical Biotech (HKSE:00399) Business Description